Oruka Therapeutics, Inc.
ORKA · XNASCIK 907654fmd_0K2TCKANZWCQ3BJE1APW8TRG6QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2004 to Sep 30, 2026, 72 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Research and development | 7 | 12 | 14 | 4 | 2 | 5 | 14 | 5 | 1 | 101 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 11 | 17 | 19 | 8 | 6 | 10 | 19 | 11 | 7 | 122 |
| Operating income | (11) | (17) | (19) | (8) | (6) | (10) | (19) | (11) | (7) | (122) |
| Interest expense | 0 | – | 0 | 0 | 0 | 0 | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 17 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | – | – | 17 |
| Income before taxes | – | (16) | (19) | (8) | (6) | (10) | (19) | – | – | (105) |
| Income tax expense | 0 | 0 | (0) | (0) | (0) | (0) | 0 | 0 | 0 | – |
| Net income from continuing operations | – | (16) | (18) | (8) | (5) | (10) | (19) | – | – | – |
| Net income | (11) | (16) | (18) | (8) | (5) | (10) | (19) | (10) | (5) | (105) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |